Bio-Rad Laboratories, Inc.
BIO
$238.68
-$2.34-0.97%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 585.40M | 667.48M | 649.73M | 638.48M | 610.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 585.40M | 667.48M | 649.73M | 638.48M | 610.80M |
| Cost of Revenue | 274.80M | 325.56M | 293.83M | 282.76M | 284.40M |
| Gross Profit | 310.60M | 341.91M | 355.90M | 355.72M | 326.40M |
| SG&A Expenses | 193.50M | 204.36M | 200.34M | 195.72M | 210.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 528.50M | 609.55M | 585.16M | 537.98M | 559.10M |
| Operating Income | 56.90M | 57.93M | 64.57M | 100.50M | 51.70M |
| Income Before Tax | 83.40M | -908.92M | 861.62M | -2.79B | 491.10M |
| Income Tax Expenses | 19.40M | -193.12M | 208.45M | -620.80M | 107.20M |
| Earnings from Continuing Operations | 64.00M | -715.80M | 653.17M | -2.17B | 383.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.00M | -715.80M | 653.17M | -2.17B | 383.90M |
| EBIT | 56.90M | 57.93M | 64.57M | 100.50M | 51.70M |
| EBITDA | 95.00M | 97.13M | 103.47M | 136.90M | 88.80M |
| EPS Basic | 2.29 | -25.57 | 23.37 | -76.26 | 13.46 |
| Normalized Basic EPS | 1.89 | 1.40 | 1.49 | 2.37 | 1.67 |
| EPS Diluted | 2.29 | -25.57 | 23.34 | -76.26 | 13.45 |
| Normalized Diluted EPS | 1.88 | 1.40 | 1.49 | 2.37 | 1.67 |
| Average Basic Shares Outstanding | 27.94M | 28.00M | 27.95M | 28.40M | 28.52M |
| Average Diluted Shares Outstanding | 27.96M | 28.00M | 27.99M | 28.40M | 28.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |